Aperio Group LLC increased its position in shares of Astrazeneca PLC (NYSE:AZN) by 13.0% during the second quarter, Holdings Channel reports. The firm owned 728,035 shares of the company’s stock after buying an additional 83,504 shares during the period. Aperio Group LLC’s holdings in Astrazeneca PLC were worth $24,819,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in the stock. Tompkins Financial Corp raised its position in Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock worth $100,000 after buying an additional 1,422 shares during the period. Meeder Asset Management Inc. acquired a new position in Astrazeneca PLC during the second quarter worth $105,000. Salem Investment Counselors Inc. acquired a new position in Astrazeneca PLC during the first quarter worth $107,000. Tower Research Capital LLC TRC raised its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares during the period. Finally, Quadrant Capital Group LLC raised its position in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock worth $138,000 after buying an additional 2,805 shares during the period. 14.01% of the stock is owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE:AZN) traded up 0.09% during mid-day trading on Wednesday, hitting $33.54. The stock had a trading volume of 1,455,913 shares. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. The company has a market cap of $84.92 billion, a PE ratio of 25.12 and a beta of 0.77. The firm’s 50-day moving average price is $34.25 and its 200 day moving average price is $31.10.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, April 27th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.61. Astrazeneca PLC had a return on equity of 35.65% and a net margin of 15.21%. The firm had revenue of $5.41 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same quarter in the prior year, the company earned $0.95 EPS. Astrazeneca PLC’s revenue was down 11.6% on a year-over-year basis. On average, equities research analysts anticipate that Astrazeneca PLC will post $1.85 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://stocknewstimes.com/2017/07/19/astrazeneca-plc-azn-shares-bought-by-aperio-group-llc.html.
AZN has been the subject of a number of recent research reports. BidaskClub lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Jefferies Group LLC reissued a “hold” rating on shares of Astrazeneca PLC in a report on Monday, April 10th. Credit Suisse Group raised shares of Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a report on Friday, May 12th. UBS AG lowered shares of Astrazeneca PLC from a “buy” rating to a “neutral” rating and cut their target price for the company from $35.44 to $25.55 in a report on Wednesday, April 5th. Finally, Leerink Swann reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Astrazeneca PLC in a report on Wednesday, May 17th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $34.13.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
